Highest-materiality recent filing
Pennant Group Q2 2026: GAAP EPS $0.25, revenue up 35.8% to $298M; on pace to exceed guidance
GAAP diluted EPS $0.25; adjusted diluted EPS $0.36; net income $9.1M (+28.2% YoY).
Pennant Group Q1 GAAP EPS $0.24, revenue $285.4M (+36%); adjusted EPS $0.32
GAAP diluted EPS $0.24; adjusted diluted EPS $0.32, up 33% YoY.
Pennant Group Q4 revenue $289.3M (+53% YoY); FY2025 GAAP EPS $0.84, adjusted EPS $1.18
Full year revenue $947.7M (+36.3% YoY); net income $29.6M (+31.1% YoY).
Acquisition of home health/hospice subsidiaries from UnitedHealth and Amedisys closed on October 1, 2025.
Pennant Group Q3 revenue up 26.8% to $229M; adjusted EPS $0.30; completes 54-location acquisition
GAAP diluted EPS $0.17; adjusted diluted EPS $0.30; adjusted net income $10.4M (+27.6% YoY).
Pennant closes $146.5M purchase of 54 home health/hospice locations in TN, GA, AL from UnitedHealth
Purchase price $146.5M; trailing twelve-month revenue of acquired operations $189.3M.
Pennant completes $146.5M acquisition of 54 home health/hospice locations from UnitedHealth/Amedisys
Acquisition includes home health, hospice and personal care operations in Tennessee, Georgia and Alabama.
Purchase price increased from $102.5M to $146.5M via First Amendment; adds entities and locations.
Pennant Q2 2025: GAAP EPS $0.20, adjusted $0.27; revenue up 30.1% to $219.5M
Net income $7.1M (+24.5% YoY); adjusted net income $9.4M (+28.2%); adjusted EBITDA $16.4M (+24.5%).
Pennant Group Q1 GAAP EPS $0.22, revenue up 33.7% to $209.8M; beats prior year substantially
GAAP diluted EPS $0.22; adjusted diluted EPS $0.27; net income $7.8M (+58.5% YoY).
Pennant Group to acquire home health/hospice assets from UnitedHealth/Amedisys for $102.5M
Acquisition price $102,484,000, subject to pre- and post-closing adjustments, paid in cash.
Pennant Group Q4/FY2024: revenue up 27.6% to $695M; adj. EPS $0.94
GAAP diluted EPS $0.70 full year, $0.16 Q4; adjusted diluted EPS $0.94 full year, $0.24 Q4.
Pennant completes $48.5M Oregon acquisition of Signature Healthcare at Home
Oregon portion closed Jan 1, 2025; total two-stage acquisition now complete.
Pennant Group Q3 net income up 42% to $6.2M; revenue rises 29% to $180.7M
GAAP diluted EPS $0.20; adjusted diluted EPS $0.26 for Q3 2024.
Pennant Group closes public offering of 4,025,000 shares, net proceeds ~$118.5M
Issued 4,025,000 shares at a public offering, including full underwriter option exercise of 525,000 shares.
Pennant Q2 revenue up 27.6% to $168.7M; EPS $0.18, adj. EPS $0.24
GAAP diluted EPS $0.18; adjusted diluted EPS $0.24. Net income $5.7M (+103.4% YoY).
Pennant Group increases credit facility by $100M to $250M, extends maturity to 2029
New $250M credit facility replaces prior $150M facility, adding $100M in borrowing capacity.
Pennant Group agrees to buy Signature Healthcare at Home assets for $80M
$80M purchase price covers affiliates in OR, WA, ID; two separate purchase agreements.
Pennant Group Q1 2024: revenue $156.9M (+24%), adj EPS $0.20, net income up 165%
GAAP EPS $0.16, adjusted EPS $0.20; adjusted net income $6.0M up 55% YoY.
Pennant Q4 revenue $146M (+17% YoY), adj. EPS $0.22; FY revenue $545M (+15%)
GAAP diluted EPS $0.14 (Q4) and $0.44 (FY); adjusted EPS $0.22 (Q4) and $0.73 (FY).
Pennant Group Q3 GAAP EPS $0.15, adjusted $0.20; revenue $140.2M up 18.5% YoY
GAAP diluted EPS $0.15, adjusted diluted EPS $0.20; net income $4.4M up 44.4% YoY.
Pennant Group Q2 GAAP EPS $0.09, adj. EPS $0.18; revenue up 13.7% to $132.3M
Total revenue $132.3M (+13.7% YoY); GAAP net income $2.8M (+204.5%); adjusted net income $5.4M (+30.4%).
Pennant Group Q1 GAAP EPS $0.06, adjusted $0.13; revenue $126.5M (+11% YoY)
GAAP diluted EPS $0.06; adjusted diluted EPS $0.13; net income $1.9M (+82.4% YoY).
GAAP diluted EPS Q4 $0.12, full year $0.22; adjusted diluted EPS Q4 $0.18, full year $0.57.
Pennant Group Q3 revenue up 5.7% to $118.4M; GAAP EPS $0.16, adjusted $0.14
Total revenue $118.4M (+5.7% YoY); net income $4.8M; adjusted EBITDA $7.9M (+21.6%).
Pennant reports Q2 GAAP loss of $0.09, adjusted EPS $0.14; revenue $116.3M up 5.4% YoY
GAAP diluted loss per share $0.09; adjusted diluted EPS $0.14.
CEO Daniel Walker resigns effective Aug 1; consulting agreement through Dec 31
Daniel Walker resigned as CEO effective August 1, 2022; consulting agreement runs through December 31, 2022.
Pennant Group CEO Daniel Walker to step down August 1; President Brent Guerisoli named CEO
Daniel Walker resigns as CEO effective Aug 1, 2022, remains Chairman of the Board.
Pennant Group Q1 2022: GAAP EPS $0.03, adj. EPS $0.11; revenue $113.9M (+7.8% YoY)
Net income $1.0M; adjusted EBITDA $6.1M; adjusted EBITDAR $15.2M.
Pennant Q4 GAAP loss per share $0.08; full year revenue rises 12.5% to $439.7M
GAAP diluted EPS: full year $0.09, Q4 $(0.08); adjusted EPS: full year $0.46, Q4 $0.07.
Pennant to transfer operations of five senior living communities to Ensign, expects accretion
Transfer of 5 senior living communities in WA, AZ, CA to Ensign affiliates; closes H1 2022 subject to approvals.
Pennant Group Q3 GAAP EPS $0.04, adjusted $0.11; revenue $111.9M (+13.7% YoY)
GAAP diluted EPS $0.04, adjusted diluted EPS $0.11; net income $1.2M.
Pennant pre-announces weak Q3; cuts FY2021 adj. revenue and EPS guidance
Preliminary Q3 adj. revenue $111.9M; net income $1.2M (diluted EPS $0.04); adj. EPS $0.11.
Pennant Group Q2 GAAP EPS $0.09, adjusted $0.17; revenue $110.3M (+19% YoY)
Total revenue $110.3M, up 19.0% YoY; Home Health & Hospice segment revenue $78.1M (+34.7%).
Effective May 22, 2023, the Board of Directors (the “Board”) of The Pennant Group, Inc. (the “Company”) appointed Ms. Lynette B. Walbom, age 46, as the Company’s Chief Financial Officer.
Also effective May 22, 2023, Ms. Jennifer L. Freeman stepped down from her role as the Company’s Interim Chief Financial Officer.
the Board appointed (i) Mr. Barry Smith as Chairman of the Board
On February 28, 2023, Mr. Daniel Walker notified the Board of Directors (the “Board”) of The Pennant Group, Inc. (the “Company”) of his resignation as Chairman of the Board.
Mr. Bunker’s resignation is effective December 31, 2022.
Pennant’s current CFO, Jennifer L. Freeman, will act as interim CFO until a new CFO is appointed.
As previously disclosed, Mr. Daniel Walker resigned as the Chief Executive Officer of The Pennant Group, Inc. (the “Company”), effective August 1, 2022.
Also on June 7, 2022, the Board appointed (i) Mr. Brent Guerisoli, the Company’s current President, as Chief Executive Officer, and (ii) Mr. John Gochnour, the Company’s current Chief Operating Officer, as President, with both such appointments to be effective August 1, 2022.
Also on June 7, 2022, the Board appointed (i) Mr. Brent Guerisoli, the Company’s current President, as Chief Executive Officer, and (ii) Mr. John Gochnour, the Company’s current Chief Operating Officer, as President, with both such appointments to be effective August 1, 2022.
On June 7, 2022, Mr. Daniel Walker notified the Board of Directors (the “Board”) of The Pennant Group, Inc. (the “Company”) of his resignation as Chief Executive Officer of the Company, effective August 1, 2022.
the Board of Directors (the “Board”) of The Pennant Group, Inc. (the “Company”), upon the recommendation of the Nominating and Governance Committee (the “Nominating Committee”) of the Board, appointed Gregory K. Morris to serve on the Board of the Company effective January 1, 2022.
Mr. Roderic W. Lewis has informed The Pennant Group, Inc. (the “Company”) of his decision to resign from its Board of Directors (the “Board”) for personal reasons, effective December 31, 2021.
Max materiality 0.85 · Median 0.65 · Most common event earnings